{
    "Trade/Device Name(s)": [
        "Wondfo Cocaine Urine Test (COC100)",
        "Wondfo Cannabinoids Urine Test (THC40)"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K131754",
    "Predicate Device Reference 510(k) Number(s)": [
        "K050394"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO",
        "LDJ"
    ],
    "Summary Letter Date": "July 2, 2013",
    "Summary Letter Received Date": "July 8, 2013",
    "Submission Date": "July 28, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.3250",
        "21 CFR 862.3870"
    ],
    "Regulation Name(s)": [
        "Cocaine test system",
        "Cannabinoid test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine",
        "11-nor-\u03949-THC-9-COOH"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow assay"
    ],
    "Methodologies": [
        "Competitive binding",
        "Antigen-antibody immunochemistry",
        "Lateral flow immunochromatography"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo Cocaine Urine Test (COC100) and Wondfo Cannabinoids Urine Test (THC40), lateral flow immunochromatographic urine assays for qualitative drug detection.",
    "Indications for Use Summary": "Qualitative, prescription-use immunochromatographic assays for detection of Benzoylecgonine (COC100) and 11-nor-\u03949-THC-9-COOH (THC40) in human urine, not intended for point-of-care use.",
    "fda_folder": "Toxicology"
}